Novo Nordisk's CFO reveals that traditional prescription tracking services like IQVIA are not built for modern, telehealth-driven distribution models. Their models only capture an estimated 60% of the actual market for self-pay drugs, creating a significant data gap for investors and analysts.

In an aggressive commercial move, Novo Nordisk partnered with telehealth company Hims to distribute its branded obesity drug. This is notable because Hims was recently reprimanded by the FDA for trying to sell a compounded version. Novo is turning a potential adversary into a distribution channel to maximize market reach.

The emergence of low-cost, compounded versions of GLP-1 drugs from telehealth companies like Hims is creating significant pricing pressure on market leaders Novo Nordisk and Eli Lilly. This dynamic has pushed the pharma giants toward direct-to-consumer models with lower prices to compete.

Unlike incumbents, new biotech and pharma companies often lack established sales forces. They launch with a 'digital first' go-to-market strategy, turning to platforms like Doximity early in their lifecycle. This creates a new and rapidly growing customer segment for Doximity, independent of the incumbents' slower transition.

The introduction of oral GLP-1 medications is proving to be a market expansion strategy, not a cannibalization one. Data shows that the majority of patients starting on oral versions are new to the GLP-1 category entirely, indicating the new form factor overcomes a key barrier to adoption.

Novo priced the maintenance dose of its oral Wegovy pill far lower than anticipated. This aggressive strategy, costing less than the average U.S. monthly grocery bill (~$400), is a direct attempt to regain momentum from rival Eli Lilly and expand the self-pay market before more oral competitors launch.

Despite concerns about cannibalizing its injectable user base, Novo Nordisk found that approximately 80% of patients taking the new Wegovy pill are new to the treatment segment. This demonstrates that introducing a new form factor can be a powerful market expansion strategy.

Eli Lilly's oral GLP-1 is proving to be a market expander, not just a cannibalizer of injectables. An overwhelming 80% of its users are new to the GLP-1 class, driven by an aggressive direct-to-consumer (DTC) telehealth strategy. This signals a vast, untapped patient population for oral obesity treatments.

Companies like "Prescriberee" operate with a business model targeting life sciences firms as clients. Their goal is not holistic care but efficiently converting interested patients into prescriptions, with one executive citing a 90% conversion rate for eligible patients.